Magnolia Medical Technologies
Inventors of the Initial Specimen Diversion Technology™
Newly Released: Cost-Benefit Analysis
A University of Houston published study concludes hospitals can save up to $367 per blood culture.
A Partnership Inspired by Evidence
We are pleased to announce our partnership with the Center for Phlebotomy Education. Discover new evidence-based education, training and earn CEU credit.
Partnering with you to significantly reduce blood culture contamination
The Steripath® Gen2 Initial Specimen Diversion Device (ISDD®) has been shown in independent clinical trials to significantly reduce preventable blood culture contamination and false-positive results for bloodstream infections and sepsis.